Influence
March 31, 2022

Regenstrief researcher will be part of life sciences expert panel

Regenstrief Research Scientist NiCole Keith, PhD, will join other Central Indiana life sciences leaders to discuss Indiana’s life-sciences industry.

The panel will elaborate on the pandemic’s effect on research and product development, federal policies and industry trends, and venture capital investments in Indiana companies, among other subjects. In addition to Dr. Keith, featured panelists are Kent Hawryluk, MBX Biosciences, Inc.; Marcela A. Kirberger, Elanco Animal Health, Inc.; Theresa S. Mayer, Purdue University; and Brandy Matthews, Eli Lilly and Company. The discussion will be moderated by Indianapolis Business Journal reporter John Russell.

Dr. Keith is a physical activity researcher specializing in community-based participatory research with a focus on health equity. She co-created the Physically Active Residential Communities and Schools (PARCS) program — a partnership among Indianapolis Public Schools, Eskenazi Health Federally Qualified Health Centers and IUPUI. This award-winning program provides exercise opportunities for more than 3,000 adults and children living in Indianapolis inner-city communities. She also helped to write the State of Aging in Indiana report.

In addition to her role as a research scientist at Regenstrief, Dr. Keith is the associate dean of faculty affairs and a professor at Indiana University School of Health & Human Sciences. Dr. Keith was the 2020-2021 president of the American College of Sports Medicine, an Indianapolis-based organization of more than 55,000 members.

The expert panel will be featured as part of the IBJ Power Breakfast Series.

register here

Related News

Aaron Carroll, M.D.

Call for Papers on Artificial Intelligence Applied to Pediatric Care

Published in JAMA Pediatrics. Here is a link to the article. Regenstrief Institute author: Aaron E. Carroll, M.D., M.S.

Critical gap in colorectal cancer screening process: follow-up after positive stool test

INDIANAPOLIS – Screening for colorectal cancer presents a unique opportunity unavailable for most other types of cancers. Screening allows